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1. Introduction  
Clinical research industry has grown around the world at 
an unbelievable rate in the past few years. The main 
survival point of the pharmaceutical industry is innovation 
and for introducing new drugs in the market, the 
companies have to conduct clinical trials as per ICH GCP 
guidelines as well as guidelines of the country where trial 
is planned. Pharmacovigilance is an important and integral 
part of clinical research. Both clinical trials safety and post 
marketing pharmacovigilance are critical throughout the 
product lifecycle especially in ensuring the safety.
 1
 
According to the World Health Organization, 
pharmacovigilance is defined as the science and activities 
relating to the detection, assessment, understanding and 
prevention of adverse eﬀects or any other possible drug-
related problem, particularly long term and short term 
adverse effects of medicines.
2
 Systematic  
pharmacovigilance  is  essential  to  build  up  reliable  
information  on  the  safety  of  all category   medicines  
for  the  development of appropriate guidelines for safe 
effective use. It basically involves identification and 
evaluation of safety signals. Some of the frequently used 
terms are defined in Table 1. 
 
Table 1: Definitions of terms related to pharmacovigilance 
Term  Definition Ref 
Adverse event An adverse event is defined as any un toward medical occurrence that may present during 
treatment with a drug but which does not necessarily have a relationship with its use. 
4 
Adverse drug 
reaction 
An adverse drug reaction (ADR) is any noxious, unintended and undesired effect of a drug, 
which occurs at a dose used in human for prophylaxis, diagnosis, therapy or modification of 
physiological function. 
6 
Post marketing 
surveillance 
Post-marketing surveillance (PMS) is the practice of monitoring the safety of 
a pharmaceutical drug or device after it has been released in the market.  
7 
Clinical trials Clinical trials are sets of tests in medical research and drug development that generate safety 
and efficacy data (or more specifically, information about adverse drug reactions and 
adverse effects of other treatments) for health interventions (e.g., drugs, diagnostics, 
devices, therapy protocols). 
9 
Safety signals Safety signal refer to a concern about an excess of adverse events compared to what would 
be expected to be associated with products use, which can arise from post marketing data 
and other sources, such as pre clinical data and events associated with other products in the 
same pharmacological class. 
11 
 
Pharmacovigilance has constantly grown in importance in 
last 10 years, relating to absolute amount of adverse drug 
reactions (ADRs) and to the fact that several hospital 
admissions are due to ADR with considerable social costs. 
The ADR percentage detected as preventable ranges from 
35% to 50%, with implicit rejections on the social welfare. 
3
 Therefore, a strong need was felt to monitor the effect of 
drugs after its launch in the market i.e., post marketing 
surveillance. The practice of science of pharmacovigilance 
emerged after well known thalidomide tragedy of the 
1960’s which led to the development of the first 
spontaneous reporting system of ADRs.
4
 Major incidences 
of drug induced toxicity reported across the globe are 
given in Table 2. 
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Table 2: Examples of major induced toxicities, reported in post marketing surveillance 
Year Drug Toxicity Remark 
1950 Chroramphenicol Aplastic anemia Still continued 
1961 Thalidomide Phocomelia National disaster 
1970 Clioquinol SMON After 30 years of use 
1970 Diethylstilbestrol Adenocarcinoma of the cervix In utero exposure 
1975 Practolol Oculo-mucocutaneous 
syndrome 
5 years after marketing 
1976 Zomepirac  Anaphylaxis Withdrawn 
1978 Phenformin Lactic acidosis Withdrawn  
1980 Ticrynafen Deaths from liver 
Disease 
Detected after 5 years of  suspection 
1982 Ticrynafen Hepatitis Withdrawn  
1990 Etretinate Birth defect High risk of birth-defect, narrow therapeutic index 
1999 Astimizole Arrhythmias Because of interaction with other drugs 
2004 Rofecoxib Myocardial infarction Withdrawn  
2007 Inhaled insulin Long term safety, high cost Withdrawn in the UK due to poor sales caused by national 
restriction on prescribing, doubts over long term safety. 
2010 Rosiglitazone Heart attacks Withdrawn in Europe  
2011 Drotrcogin alfa Prowess -shock study Withdrawn by Lily 
2012 Rimonabant Depression, risk of suicidal 
tendencies and seizures  
Withdrawn  
2012 Sibutramine Heart related side effects Banned  
 
2. Aims of Pharmacovigilance  
Pharmacovigilance is the science of collecting, monitoring, 
researching, assessing and evaluating information from 
healthcare providers, pharmaceutical companies and 
patients on the adverse effects 
of medications, biologicals, herbal and traditional 
medicines. Pharmacovigilance is used in different sectors 
as shown in Fig. 1.    
 
Figure 1: Pharmacovigilance in different sectors. 
Pharmacovigilance involves monitoring and assessing the 
quality of drugs along with detection and prevention of any 
adverse effect of drugs with following objectives:
5
 
 To identify new information about hazards associated 
with medicines. 
 To prevent harm to the patients. 
 To improve patient care and safety in relation to the 
use of medicines, and all medical and paramedical 
interventions. 
 To improve public health and safety in relation to the 
use of medicines. 
 To contribute to the assessment of benefit, harm, 
effectiveness and risk of medicines, encouraging their 
safe, rational and more effective (including cost-
effective).  
 To promote understanding, education and clinical 
training in pharmacovigilance and its effective 
communication to health professionals and the public.
6
 
 To identify risk factors and possible mechanisms 
underlying adverse reactions. 
 To estimate quantitative aspects of benefit/risk 
analysis and dissemination of information needed to 
improve drug prescribing and regulation. 
3. Role of Pharmacovigilance 
The role of pharmacovigilance is to check the safety 
monitoring in clinical trials involves collecting adverse 
events, laboratory investigations and details of the clinical 
examination of patients. Pharmacovigilance staff may be 
involved to varying degrees in all phases of clinical trials, 
including the planning, execution, data analysis and 
reporting of safety.
7
 Pharmacovigilance approve the drug 
regulatory authorities needs to go further than the approval 
of new medicines, to encompass a wider range of issues 
relating to the safety of medicines, namely: 
 Clinical trials;  
 The safety of complementary and traditional 
medicines, vaccines and biological medicines; 
 The receipt, processing and reporting of adverse event 
reports; 
 Following-up with reporters to obtain further details 
about a case report; 
 Providing an information service to healthcare 
professionals and patients on product safety; and 
 Providing safety expertise to internal cross-functional 
colleagues. 
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Pharmacovigilance programmes need to maintain strong 
links with the drug regulatory authorities to ensure that the 
latter are well briefed on safety issues in everyday clinical 
practice, whether these issues are relevant to future 
regulatory action or to concerns that emerge in the public 
domain. 
8
 On the other, regulators need to understand the 
specialized and pivotal role that pharmacovigilance plays 
in ensuring the ongoing safety of medicinal products.  
4. Pharmacovigilance of Herbal Medicines 
Now a day’s herbal medicine are very popular in general 
public but the safety of these remedies are major issue for 
public health. The use of herbs in traditional medicines 
continues to expand rapidly across the world.
9
 In various 
national health-care settings for the health of the patients,  
herbal products have a very large share almost prescribed 
medicines. However, mass media reports of adverse events 
tend to be sensational and give a negative impression 
regarding the use of herbal medicines in general rather 
than identifying the causes of these events, which may 
relate to a variety of issues. 
10
 Monitoring of  herbal  safety  
but  require  modiﬁcation  to address  speciﬁc  challenges  
such  as  botanical  nomenclature,  quality, adulteration,  
labeling  issues,  prescriber/reporter  differences  and 
under-reporting. 
11
 
5. Pharmacovigilance Methods 
As per International Conference on Harmonization 
Efficacy Guidelines 2 (ICHE2E) guidelines, the 
pharmacovigilance methods can be categorized as: 
Passive surveillance 
(a) Spontaneous reporting system (SRS) 
(b) Case series 
Stimulated reporting 
Active surveillance 
(a) Sentinel sites 
(b) Drug event monitoring 
(c) Registries 
Comparatives observational studies 
(a) Cross sectional study 
(b) Case control study 
(c) Cohort study 
Targeted clinical investigations 
Descriptive studies 
(a) Natural history of disease 
(b) Drug utilization study 
Pharmacovigilance methods can be also classified as 
hypothesis generation methods and hypothesis testing 
method as follows: 
 Hypothesis generating methods 
(a) Spontaneous ADR reporting 
(b) Prescription event monitoring 
Hypothesis testing methods 
(a) Case control study 
(b) Cohort studies 
(c) Randomized controlled trials 
Most frequently used methods for monitoring of drug 
safety are as follows:  
5.1  Spontaneous reporting systems   
Recording and reporting clinical observations of a 
suspected ADR with a marketed drug is known as 
spontaneous or voluntary reporting.
12
 There  are  subtle  
differences  between countries  but  the  principles  are  the  
same. The national system based on this in the UK is the 
‘Yellow Card’ scheme, where doctors, dentists, and 
recently, hospital pharmacists are encouraged to report all 
suspected reactions to new medicines and serious 
suspected reactions to established medicines. Safety of 
medicines is commonly monitored through spontaneous 
reporting systems.
13
 Standardized  forms  are used  for  
reporting  of  suspected  adverse  reactions  to  the  
regulatory authorities  by  medical  professionals,  
including  physicians,  pharmacists,  nurses  and  in  some  
countries,  by consumers.  The reports are of ‘suspected’ 
adverse reactions, and a reporter does not have to conﬁrm 
the association between drug and effect. 
14
 
Spontaneous  reports  are  more  likely  to  be  effective  
where products are regulated as medicines and also where 
products are supplied  by  health  professionals,  who  are  
well  informed  in  the  use of  this  reporting  system.  
Consumers  may  not  be  aware  of  the  importance  of  
reporting  adverse  effects.
15 
Spontaneous reporting of 
adverse drug reaction and adverse events is an important 
tool for gathering the safety information for early 
detection, case reports collected by such system represent 
the source of information providing the lowest level of 
evidence and highest level of uncertainty regarding 
casualty.
16  
Spontaneous reporting has advantages in that it 
is available immediately after a new product is marketed, 
continues indefinitely and covers all patients receiving the 
drug. It is the most likely method of detecting new, rare 
ADRs and frequently generates safety signals which need 
to be examined further.
17 
The main limitations are the 
difficulty in recognizing previously unknown reactions, 
particularly events that are not usually thought of as being 
ADRs and under-reporting, which is variable, sensitive to 
reporting stimuli and difficult to quantify. It usually does 
not confirm hypotheses; although situations exist where 
spontaneous reporting data alone allow conclusions that a 
signal indeed represents a true ADR. 
18
 
5.2  Prescription-event monitoring (PEM) 
PEM is a non-interventional, observational cohort form of 
pharmacovigilance. PEM studies are cohort studies where 
exposure is obtained from a centralised service and 
outcomes from simple questionnaires completed by 
general practitioners. 
19
 Follow-up forms are sent for 
selected events. Because PEM captures all events and not 
only the suspected ADRs, PEM cohorts potentially differ 
in respect to the distribution of number of events per 
person depending on the nature of the drug under study. 
This variance can be related either with the condition for 
which the drug is prescribed (e.g. a condition causing high 
morbidity will have, in average, a higher number of events 
per person compared with a condition with lower 
morbidity) or with the drug effect itself. 
20 
5.3  Targeted Clinical Investigations (TCI) 
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When significant risks are identified from pre-approval 
clinical trials, further clinical studies might be called for 
evaluate the mechanism of action for the adverse reaction. 
In some instances, pharmacodynamics and 
pharmacokinetics studies might be conducted to determine 
whether a particular dosing instruction can put patients at 
an increase risk of adverse events. Genetic testing can also 
provide clues about which group of patients might be at an 
increased risk of adverse reactions. Furthermore specific 
studies to investigate potential drug-drug interactions and 
food-drug interactions needs to be conducted based on the 
pharmacological properties and the expected use of the 
drug in general practice. These studies can include 
population pharmacokinetic studies and drug concentration 
monitoring in patients and normal volunteers. 
6. Pharmacovigilance: Reporting and Functioning 
To fulfil the pharmacovigilance obligations for its 
marketed products as per regulations, a pharmaceutical 
company in India has to essentially carry out activities 
such as collection, included expedited reporting of serious 
unexpected adverse reactions and preparations. 
21
 
A typical setup for pharmacovigilance studies, people 
involved on various levels, organizational units and their 
functions are given as Fig. 2.
 
 
Figure 2: A typical pharmacovigilance setup: People involved, functions and structure 
 
6.1  Detection and reporting 
Physician has most important role to play in 
pharmacovigilance. Not merely because he is the first 
person to whom the patient will come with symptoms; but 
also to suspect an ADR. 
22
 A healthcare professional or 
marketing authorization holder reports a suspected adverse 
drug reaction related to one or more medicinal products, to 
a national competent authority (pharmacovigilance centre). 
Reports are made in writing (e.g. using report forms), by 
telephone, electronically, or by any other approved way. 
23
 
Reports are collected and validated by the 
pharmacovigilance centre and are usually entered into a 
database. Serious reactions should be handled with the 
highest priority. The database is used to identify potential 
signals and analyze data in order to clarify risk factors, 
apparent changes in reporting profiles etc. 
24
. A typical 
ADR reporting form is given as Fig. 3. 
6.2  Case report collection and validation  
This concerns the collection and validation of primary data 
i.e. the data transmitted from the reporter to the competent 
authority. For the validation and management of 
electronically transmitted reports, the specific operational 
procedure should be followed.
25
A pharmacovigilance 
spontaneous report concerns a single case; one patient, one 
identifiable reporter, one or more suspected reactions, and 
one or more suspect medicinal products. According to 
European Directives and Regulations, only serious cases 
reported by healthcare professionals will be received on an 
expedited basis.
26
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Figure 3: ADR reporting form. 
7. Clinical Trials in India 
7.1  India: A preferred destination for clinical trials 
Global pharmaceutical companies have found India's 
clinical research space and opportunity very attractive 
27
. 
India born CROs were able to offer the advantages of 
understanding the Indian scenario better, provide services 
at more competitive costs, and having better knowledge
28
 
of Investigator sites in the country compared to the newer 
entrants in the market. India’s existing favourable 
regulatory framework and regulations with international 
standards, increasing awareness of good clinical practice 
guidelines and its implementation by clinicians are some 
of the main reasons propelling the growth of clinical 
research in India.
29
 The average annual report of clinical 
trials conducted in India is shown as Fig. 4. 
30
  
 
Figure 4: Growth of clinical trials in India. 
30 
 
The therapeutic areas wise distribution of clinical trials and 
availability of diverse patient population across major 
therapeutic segments such as oncology, metabolic, 
neurology etc. in India is shown in Fig. 5. 
31
 
Some of the advantages that India offers as clinical trials 
destination are as follows: 
 High degree of compliance to international guidelines 
such as the ICH GCP and the regulations lay down by 
the US Food and Drug Administration. 
 Availability of well qualified, English speaking 
research professionals including physicians. 
 Ongoing support and cooperation from the 
government. 
 Lower cost compared to the west. 32 
 Increasing prevalence of illnesses common to both 
developed and developing countries. 
 Availability of good infrastructure. 
 Changes in Patent Laws since January 2005. 
As per a recent report from FICCI, scientific feasibility, 
medical infrastructure, clinical trial experience, 
regulations, commercialization potential and cost 
competitiveness are some of the growth drivers responsible 
for the metamorphosis of Indian clinical research in the 
recent past. 
33 
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Figure 5: Therapeutic area wise distribution of clinical 
trials outsourced to India. 
7.2 SWOT Analysis of Indian Clinical Trial Sector 
 Strengths 
 Large population of over 1.2 billion, about 16% of 
the world’s population.  
 Huge pharmaceutical and biotech industry 
base with availability of skilled persons.  
 3 rd largest players in the world with 500 
different APIs.  
 Current by account for 8% of global 
pharmaceutical production, being 4
th
 in the 
world.
34
 
 Conducive initiatives to harness innovative 
capability by government.  
 Possibility of huge data mining related to  
safety profile of drugs due to large 
population.
3 5
 
Weaknesses 
 As per 2009-10 estimates, expenditure on health 
sector was 2.1% or the total budget and 
0.35% of the GDP of India.
36
 
 Developed countries like United States, France, 
Switzerland and Germany, spent around 16%, 11%, 
10.8% and 10.4% of their GDP respectively.                                                                                              
 Less funding available for implementation of 
programs and issues of national importance such as 
pharmacovigilance.
37
    
Opportunities 
 Indian population is the largest source of the human 
biodiversity. 
 Consisting of 4635 culturally and 
anthropologically well -defined populations, 
representing a perfect model to study 
efficacy, disease susceptibility, etiology, molecular 
pathology, and safety profile of drugs with respect to 
genetic diversity.     
 Excellent potential for skilled human resources 
required for an effective pharmacovigilance system 
due to >300,>230 dental, >830 pharmacy and >650 
recognized nursing colleges in India. 
38
 
Threats 
 Under reporting of ADRs. 
 Low availability of funds. 
 Less ADRs monitoring centers. 
8. Agencies Involved for Clinical Research Regulation 
In India 
Various agencies of India with their prominent role in 
overseeing clinical trial along with Ethics committee are 
given in Table 3.
39
 
Table 3: Roles of various regulatory agencies 
   Agencies                                  Role of agencies 
Drug Controller General of India (DCGI) Implementation the National Pharmacovigilance Program (NPP) in India. 
Central Drugs Standard Control 
Organization (CDSCO) 
Operate under the supervision of the National Pharmacovigilance Advisory 
Committee to recommend procedures and guidelines for regulatory 
interventions. 
Department of Biotechnology (DBT) Provides product evaluation and validation through support for limited and 
large scale field trials for agriculture products and clinical trials for health 
care products. 
Ministry of Environment & Forests 
(MOEF) 
PAC (Project advisory committee)   approves guidelines for making data 
entries of the information provided by the environmental experts through the 
field trials for agriculture products and clinical trials for health care products. 
Indian Council of Medical Research 
(ICMR) 
Brought out the 'Policy Statement on Ethical 
Considerations involved in Research on Human Subjects' in 1980 and 
revised these guidelines in 2000 as the 'Ethical guidelines for Biomedical 
Research on Human Subjects'. 
Central Bureau of Narcotics (CBN) Closely monitored all clinical trials, which require additional narcotics 
compliances relating to storage, import-export quotas and movement of the 
investigational drug. 
Ministry of Health and Family Welfare 
(MHFW) 
An autonomous body for setting of standards for drugs, pharmaceuticals and 
healthcare devices and technologies in India. 
National Pharmacovigilance Advisory 
Committee (NPAC) 
To collate, analyze and archive adverse drug reaction data for creating 
healthy environment for the regulatory authorities to analyze the drug to be 
marketed in India. 
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9. Pharmacovigilance in India   
9.1 The need  
Although clinical trials in India being conducted and  
started around 1996 in global market, the landmark year 
for the industry was 2005. The studies of the clinical trials 
are structured, supervised where the safety and efficacy of 
a new drug or therapy are tested in an effort to develop 
new treatments that will help those afflicted with the 
targeted condition. For conducting global clinical trials, 
India is looked upon as a better choice.
40
 India clinical 
market provides an opportunity of availability of large 
patient populations, highly educated talent, a wide 
spectrum of disease, lower costs of operations, and a 
favourable economic and intellectual property 
environment.  
In the current time, clinical research industry has grown 
around the world at an unbelievable rate with 
pharmaceutical industry. The main survival amount of the 
pharmaceutical companies is innovation through 
introducing new drugs in the market. 
41
 For approval, well 
organized, supervised and structured clinical trials have to 
be essentially conducted as per ICH GCP guidelines in 
accordance with defined rules of the country in which trial 
is planned.
42
 It is very essential as the conditions under 
which patients are studied during the pre-marketing phase 
do not necessarily reflect the way the medicine will be 
used in the hospital or in general practice once it is 
marketed. 
43
 
9.2  The development
 
India joined the World Health Organization (WHO) 
Adverse Drug Reaction Monitoring Programme based in 
Uppsala, Sweden in 1997. For the monitoring of ADR’s 
three main centres  were identified, mainly based  in 
teaching hospitals: a National Pharmacovigilance Centre 
located in the Department  of Pharmacology, All India 
Institute of Medical Sciences (AIIMS), New Delhi and two 
WHO special centers in Mumbai (KEM Hospital) and 
Aligarh (JLN Hospital, Aligarh Muslim University).
44
 The 
ADRs of the medicines which are in market for sell in 
OTC counter are monitored by these centers. This attempt 
was unsuccessful and hence, again from the 1
st
 of January 
2005, the WHO-sponsored and World Bank-funded 
National Pharmacovigilance Program for India was 
formulated.
45
 The National Pharmacovigilance Program 
established in January 2005, was to be overseen by the 
National Pharmacovigilance Advisory Committee based in 
the Central Drugs Standard Control Organization 
(CDSCO), New Delhi. Two zonal centers-the South-West 
zonal centre (located in the Department of Clinical 
Pharmacology, Seth GS Medical College and KEM 
located in the Department of Pharmacology, AIIMS, New 
Delhi), were also established to collate information from 
all over the country and send it to the Committee as well as 
to the Uppsala Monitoring centre in Sweden.
46
 The 
chronological developments in the field of 
pharmacovigilance with special reference to India are 
given as Table 4. 
Table 4: Chronological developments in pharmacovigilance sector with special reference to India 
Year Event 
1747 First reported clinical trials by James Lind, proving the effectiveness of lemon juice in preventing scurvy 
1937 Death of 107 children due to sulfanilamide toxicity 
1950 Apalstic anemia reported due to chloramphenicol 
1961 Global disaster due to thalidomide toxicity 
1963 16
th
 World Health Assembly recognize important to rapid action on ADR’s 
1968 WHO pilot research project for international drug monitoring 
1996 Clinical trials of global standards started in India 
1997 India joined WHO Adverse Drug Reaction Monitoring Program 
1998 Pharmacovigilance initiated in India 
2002 67
th
 National Pharmacovigilance Center established in India. 
2004-05 National Pharmacovigilance Program launched in India 
2005 Conduct of structured clinical trials in India 
2009-10 PVPI initiated 
 
9.3 Pharmacovigilance Program of  India (PVPI) 
Organizational structure of pharmacovigilance program of India and respective responsibilities of are given as Fig. 6. 
47 
 
Figure 6: Pharmacovigilance program in India and responsibilities. 
Sumit et al                                         Journal of Drug Delivery & Therapeutics; 2013, 3(4), 237    244 
© 2011, JDDT. All Rights Reserved                                                        ISSN: 2250-1177                                                     CODEN (USA): JDDTAO 
9.4 Formulation of India’s pharmacovigilance 
guideline 
Globally, many countries have formulated their own 
pharmacovigilance guidelines with the aim to have a 
systematic process of safety reporting. The ICH has six 
guidelines pertaining to various aspects of drug safety: 
48.49
 
E2A- Clinical Safety Data Management: Definitions and 
standards for expedited reporting, 
E2B- Clinical Safety Data Management: Data elements for 
transmission of individual case safety reports,  
E2C- Clinical Safety Data Management: Periodic safety 
update reports for marketed drugs, 
E2D- Post-approval Safety Data Management: Definitions 
and standards for expedited reporting, 
E2E-Pharmacovigilanve planning, and 
E2F- Development Safety Update Report 
The USFDA has title 21 of Code of Federal Regulations 
(mainly part 312-Investigational New Drug and part 314-
Applications for FDA Approval to Market a New Drug) 
and the EMEA has entire Volume 9A for 
pharmacovigilance in humans.
50
 In contrast, India has only 
a small section of Schedule Y dedicated to drug safety, 
which when viewed in light of contemporary global 
practice, seems to have many lacunae. It is thus a felt need 
that CDSCO must formulate a detailed pharmacovigilance 
guideline. Such guideline shall incorporate all relevant 
areas of pre and post marketing safety, address to current 
lacunae and bring about clarity on issues as discussed 
above. Most importantly, the guidelines shall be in tune 
with the current international norms, so as to support 
India’s growth as any participant in multinational clinical 
trials.
51
 
9.5 International Collaborations 
The principle of international collaboration in the field of 
pharmacovigilance is the main basis for the WHO 
International Drug Monitoring Programme, through which 
over 100 member nations have systems in place that 
encourage healthcare personnel to record and report 
adverse effects of drugs in their patients.  
The Uppsala Monitoring Centre (UMC), located in 
Uppsala, Sweden, is the field name for the WHO 
Collaborating Centre for International Drug Monitoring. 
The UMC works by collecting, assessing and 
communicating information from member countries 
national pharmacovigilance programs in regards to the 
benefits, harm, effectiveness and risks of drugs. 
52
 
The Council for International Organizations of Medical 
Sciences (CIOMS), through its Working Groups, is a 
globally-oriented think tank that provides guidance on 
drug safety related problems. CIOMS is part of WHO and 
prepares reports are used as a reference for developing 
future drug regulatory policy and procedures. 
9.6 The challenges 
ADRs are one of the leading causes of death. Most of the 
time, these dangerous events could and should have been 
avoided. Despite the fact that more adverse reactions occur 
in patients 60 or older, the odds of suffering a ADRs really 
begin to increase even before age 50. Almost half (49.5%) 
of Food and Drug Administration (FDA) reports of deaths 
from ADRs and 61% of hospitalizations from ADRs were 
in people younger than 60. The risk of a ADRs is about 
33% higher in people aged 50 to 59 than it is in people 
aged 40 to 49. Patients admitted to medical wards of a 
hospital found that although for 3.8% of hospital 
admissions, ADRs led directly to hospitalization, 57% of 
these ADRs were not recognized by the attending 
physician at the time of admission. A recent study 
concerning the reasons for paediatric hospitalization 
(children under the age of 19) found that 2.09% of all 
paediatric hospitalizations were caused by ADRs and that 
39% of these were life-threatening. 
Added to this, half of these ADRs are not recognized by 
the physicians on admission and ADRs may be responsible 
for death of huge amount of patients. Furthermore, the 
financial cost of ADRs to the healthcare system is also 
vast.
53
 In market, when the new medicines are launched 
without long term safety studies by the regulatory 
authorities, patients follow the self medication and 
switching of prescription-only medicines (POM) to over-
the-counter (OTC) more widely, and this is the main 
reason of exposing itself to ADRs. In the earlier period, 
India's regulatory agencies and drug companies based their 
safety assessments on experiences derived from long-term 
use.
54
 In recent years, many Indian companies are 
increasing the investment in research and development and 
are enhancing their capacity to develop and market new 
drugs with their own research efforts. Once a product is 
marketed, new information will be generated, which may 
have an impact on the benefit-risk profile of the product. 
The detailed evaluation of the new information generated 
through pharmacovigilance activities is important for all 
products to ensure their safe use.  
India is a vast country and there is a excess of drug brands 
more than 6,000 licensed drug manufacturers and over 
60,000 branded formulations. India is the fourth biggest 
producer of pharmaceuticals in the world and is also rising 
as a clinical trials hub. Many new drugs are being 
introduced in the country, so there is an immense need to 
improve the pharmacovigilance system to protect the 
Indian population from potential harm that may be caused 
by some of the new drugs.
55
  
In India, a pharmaceutical company holding the marketing 
license should ensure that they have adequate 
pharmacovigilance system in place to ensure the 
responsibility and liability of their marketed products. 
When two or more marketed products are identical in all 
aspects except their trade names, each pharmaceutical 
company holding a marketing license is obliged to meet 
the pharmacovigilance obligations.
56
 This includes 
establishment and maintenance of appropriate 
pharmacovigilance system to collect and evaluate 
information about suspected adverse reactions.  
9.7 Future prospects   
As the future prospects a robust, pharmacovigilance 
system capable to detect new ADRs an, taking regulatory 
actions needed to protect public health. Little emphasis has 
been put into generating information that can assist a 
healthcare professional or a patient in the decision-making 
process. The gathering and communication of this 
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information is an important goal of pharmacovigilance.
57
 
Information about the safety of drug active surveillance is 
necessary. When developing new methods for active post-
marketing surveillance, one has to keep in mind the 
importance of being able to gather information. 
Spontaneous reporting is a useful tool in generating 
signals, but the relatively low number of reports received 
for a specific association makes it less useful in identifying 
patient characteristics and risk factors.
58
 
Pharmacovigilance methods must also be able to describe 
which patients are at risk of developing an ADR. As a 
source of information pharmacovigilance approach would 
be consistent with the growing patient involvement in drug 
safety. 
At present, the DCGI should act quickly to improve 
pharmacovigilance so as to integrate Good 
Pharmacovigilance Practice (GPP) into the processes and 
procedures to help ensure regulatory compliance and 
enhance clinical trial safety and post marketing 
surveillance. An appropriately working pharmacovigilance 
system is essential if medicines are to be used carefully. It 
will be benefit for healthcare professionals, regulatory 
authorities, pharmaceutical companies and the consumers. 
It helps pharmaceutical companies to monitor their 
medicines for risk.
59 
Post-marketing pharmacovigilance is 
currently a challenging and laborious process, not only 
industry-wide, but also for regulatory agencies. 
The aim of the pharmacovigilance is to receive the 
information, documentation of the work and knowledge 
online while giving priority to the new and important 
safety issues. Non-serious events have less priority than 
serious events, although they are also screened routinely.
60
 
In present time, GSK has created a powerful new approach 
to pharmacovigilance, integrating traditional, case-based 
pharmacovigilance methods with dis-proportionality and 
data visualization tools. These tools exist within a system 
framework that facilitates in-stream review, tracking of 
safety issues and knowledge management. This very 
innovative tool and the processes will help to advance 
pharmacovigilance by improving efficiency and providing 
new analytical capabilities.
[61] 
Similar approach may be 
adopted by pharmaceutical companies for prompt 
detection and analysis of ADRs. 
10. CONCLUSION 
India is the fourth largest producer of pharmaceuticals and 
now emerging as an important clinical trial hub in the 
world. With introduction of new drugs, a robust 
pharmacovigilance system is need of the hour in our 
country to protect the population from the potential harm 
and adverse effect due to some of the new drug molecules.
 
Pharmacovigilance plays a crucial role in meeting the 
challenges posed by the ever increasing range and potency 
of medicines. But the pharmacovigilance system in India is 
still not well developed. Despite of recent implementation 
of a well structured pharmacovigilance program in India in 
accordance with the objectives and recommendations of 
WHO by CDSCO, desired success is still a distant dream. 
However increased awareness and training of public and 
medical professions, framing of strong regulations for 
reporting of ADRs, effective implementation and 
collaborative efforts between government, regulatory 
officials, pharmaceutical companies, health care 
professionals and patient may lead to an effective 
pharmacovigilance system in India to insure the 
availability of safe medicines to public. 
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